Suman Shaw

Employment

• Nirma University Institute of Pharmacy Research Scholar
  2020 - 2025

Education

• Birla Institute of Technology, Mesra Masteres in Pharmacy (Pharmaceutical Chemistry)
  2018 - 2020

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• In Search of PI3K Inhibitors as Anticancer Agents: Molecular Modelling Through Virtual Screening, ADMET, and Molecular Dynamics Simulations
  Suman K. Shaw, Rajdeep Dey, Ruchi Yadav +6 more
  ChemistrySelect 2025 DOI: 10.1002/slct.202500406
  +Save
• Morpholine-Substituted Tetrahydroquinoline Derivatives as Potential mTOR Inhibitors: Synthesis, Computational Insights, and Cellular Analysis
  Rajdeep Dey, Suman K. Shaw, Ruchi Yadav +5 more
  Cancers 2025 DOI: 10.3390/cancers17050759
  +Save
• Synthesis, biological screening, and binding mode analysis of some N-substituted tetrahydroquinoline analogs as apoptosis inducers and anticancer agents
  Rajdeep Dey, Suman K. Shaw, Hardik Bhatt +3 more
  Journal of Molecular Structure 2024 DOI: 10.1016/j.molstruc.2024.139330
  +Save
• Designing of target-specific N-substituted tetrahydroquinoline derivatives as potent mTOR inhibitors via integrated structure-guided computational approaches
  Suman K. Shaw, Rajdeep Dey, Hardik Bhatt +4 more
  ChemistrySelect 2024 DOI: 10.1002/slct.202303291
  +Save
• Synthesis, Biological Screening, and Binding Mode Analysis of Some N-Substituted Tetrahydroquinoline Analogs as Apoptosis Inducers and Anticancer Agents
  SSRN 2024 DOI: 10.2139/ssrn.4807566
  +Save
• Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer
  Udit Chaube, Rajdeep Dey, Suman K. Shaw +2 more
  Future Medicinal Chemistry 2022 DOI: 10.4155/fmc-2022-0204
  +Save
• The retroactive and future potentials of Aurora kinases in the treatment of cancer
  Hardik Bhatt, Keerti Vishwakarma, Suman K. Shaw
  Protein Kinase Inhibitors 2022 DOI: 10.1016/b978-0-323-91287-7.00016-8
  +Save
• The retroactive and future potentials of Aurora kinases in the treatment of cancer
  Hardik Bhatt, Keerti Vishwakarma, Suman K. Shaw
  Protein Kinase Inhibitors: From Discovery to Therapeutics 2022 DOI: 10.1016/B978-0-323-91287-7.00016-8
  +Save
• Morpholine-Substituted Tetrahydroquinoline Derivatives as Potential mTOR Inhibitors: Synthesis, Computational Insights, and Cellular Analysis
  DOI: 10.20944/preprints202501.1943.v1
  +Save